Clinical trial
Safety, Tolerability, Immunological and Clinical Efficacy of Multiple…
NCT00058981 · DeveloGen Israel, Ltd., Industry · Terminated
Key facts
| NCT number | NCT00058981 |
|---|---|
| Title | Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA) |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Tolerability as Well as the Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in LADA Subjects |
| Lead sponsor | DeveloGen Israel, Ltd., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes, Autoimmune |
| Intervention type | Drug |
| Interventions | DiaPep277 |
| Enrollment | 100 |
| Start date | Oct 1, 2002 |
| Primary completion | Mar 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Apr 24, 2003 |
| Last update posted | Mar 19, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: